-
Mashup Score: 3
Across five open-label phase II studies on rusfertide plus concurrent therapies, nine cases of secondary malignancies were reported among 169 total patients who received treatment, representing an incidence of 5.3%. The highest rate of malignancies was observed in patients with polycythemia vera at 6.6%. The data were presented at the 15 th International Congress on Myeloproliferative Neoplasms in Brooklyn, New York, by lead author, Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer
Source: www.bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
Intrathecal chemotherapy is “essential” to prevent central nervous system (CNS) relapse in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but the effectiveness of the prophylaxis depends upon how many times it is administered, according to recent research. Shilpa Paul, PharmD, BCOP, of the MD Anderson Cancer Center, and colleagues published their findings in correspondence to the American Journal of Hematology. They cond ucted the research because treatment
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
Intrathecal chemotherapy is “essential” to prevent CNS relapse in patients with Ph+ ALL, but the effectiveness of the prophylaxis depends upon how many times it is administered, according to a study by @SPaul_PharmD of @MDAndersonNews and colleagues. 📚 https://t.co/GXXN9nJCPz https://t.co/mXPv4HDmyF
-
-
Mashup Score: 0Toxicity Management: CAR-Ts Versus Bispecific T-Cell Engagers - 7 month(s) ago
A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer Institute at Emory University School of Medicine, focused on the latest updates in CAR T-cell therapy for multiple myeloma. Dr. Lonial w as joined by Noopur Raje, MD, and Krina Patel, MD, MSc. In the next segment of the roundtable series, the panel discusses treatment-related side effects such as CRS, ICANS, and more, and how to effectively manage these toxicities in the real world.
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
How can CRS and ICANS be effectively managed in a real-world setting? In this video, @SagarLonialMD of @WinshipAtEmory; @NoopurRajeMD of @harvardmed, @MGHCancerCenter; and @DrKrinaPatel of @MDAndersonNews, share their insights and experiences. 📺https://t.co/D2pHD66MwU #mmsm https://t.co/xhqfVjZ652
-
-
Mashup Score: 0
Othman Al-Sawaf, MD, a hematologist and oncologist at the University of Cologne in Germany, and Nicole Lamanna, MD, a Professor of Medicine at the Columbia University Medical Center, debate whether frontline venetoclax plus obinutuzumab should be limited to 12 cycles or extended to a longer duration for patients with chronic lymphocytic leukemia (CLL). To set the scene, in the phase III CLL14 trial, we explored the combination of venetoclax plus obinutuzumab in patients with previously untreated CLL. The
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
What's the best strategy for frontline venetoclax plus obinutuzumab in CLL? Don't miss the debate on the topic between Nicole Lamanna, MD, of @columbiacancer and @Othman_Al_Sawaf of @UniCologne in our latest Point | Counterpoint feature. 📚https://t.co/CJ4tQ8b9Qj https://t.co/w2plHwtyPr
-
-
Mashup Score: 1Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma - 7 month(s) ago
Home > Video Insights > Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer Institute at Emory University School of Medicine, focused on the latest updates in CAR T-cell therapy for multip le myeloma. Dr. Lonial was joined by Noopur Raje, MD, and Krina Patel, MD, MSc. In the next segment of the roundtable series, the panel discussed how CAR-T impacts
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
How do you choose between a CAR-T and a bispecific? What are the bridging therapy options? In this video, hear insights from @SagarLonialMD of @WinshipAtEmory; @NoopurRajeMD of @harvardmed, @MGHCancerCenter; & @DrKrinaPatel of @MDAndersonNews. 📺https://t.co/qx9tmmYiu5 #mmsm https://t.co/Q3JwaediVy
-
-
Mashup Score: 1Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma - 7 month(s) ago
Home > Video Insights > Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer Institute at Emory University School of Medicine, focused on the latest updates in CAR T-cell therapy for multip le myeloma. Dr. Lonial was joined by Noopur Raje, MD, and Krina Patel, MD, MSc. In the next segment of the roundtable series, the panel discussed how CAR-T impacts
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
How do you determine if a patient isn't suited for CAR-T? Hear from @SagarLonialMD of @WinshipAtEmory; @NoopurRajeMD of @harvardmed, @MGHCancerCenter; and @DrKrinaPatel of @MDAndersonNews in the third segment of this new myeloma roundtable series. 📺https://t.co/qx9tmmYiu5 https://t.co/JP5UeA5Bxo
-
-
Mashup Score: 0Dr. Konopleva on the Controversies Surrounding MRD in AML - 7 month(s) ago
Marina Konopleva, MD, PhD, of the Albert Einstein College of Medicine, joins Chadi Nabhan, MD, MBA, FACP, to discuss measurable residual disease (MRD) in acute myeloid leukemia (AML) at the Eleventh Annual Meeting of the Society of Hematologic Oncology. Dr. Konopleva discusses the measurement and clinical utility of MRD, as well as what she sees on the horizon. “I th ink it’s really controversial, but I think we are moving towards using that prognostically,” she said. “Measurements remain controversial
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
What are the controversies surrounding MRD in AML? Don't miss this video featuring @mkonople of @EinsteinMed and @MontefioreNYC discussing the topic and what she sees on the horizon with @chadinabhan at #SOHO23. 📺https://t.co/IPYRdE52N5 https://t.co/BVzZyFPWVc
-
-
Mashup Score: 0ASPEN Trial Compares Zanubrutinib with Ibrutinib in Symptomatic Waldenström Macroglobulinemia - 7 month(s) ago
Major developments in targeted therapies, particularly Bruton’s tyrosine kinase (BTK) inhibitors, have significantly improved outcomes for patients with hematologic malignancies included chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM). Ibrutinib was the first BTK inhibitor approved for patients with CLL or SLL, but was associated with some safety concerns, most notably cardiac toxicit ies. Subsequent BTK inhibitors, such as zanubrutinib, sought
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
Results from the final analysis of the phase III ASPEN trial by @thanosdimop of @uoaofficial and colleagues "confirm improved long-term safety and tolerability of zanubrutinib compared with ibrutinib" in symptomatic Waldenström macroglobulinemia. 📚https://t.co/fHrkWFiU4C https://t.co/gyYcTircnP
-
-
Mashup Score: 0Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma - 7 month(s) ago
Home > Video Insights > Treatment Sequencing Considerations for Using CAR-T in Patients with Multiple Myeloma A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer Institute at Emory University School of Medicine, focused on the latest updates in CAR T-cell therapy for multip le myeloma. Dr. Lonial was joined by Noopur Raje, MD, and Krina Patel, MD, MSc. In the next segment of the roundtable series, the panel discussed how CAR-T impacts
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
How does CAR-T impact the standard of care in myeloma? In the second segment of this all-new myeloma roundtable series, hear from @SagarLonialMD of @WinshipAtEmory; @NoopurRajeMD of @harvardmed, @MGHCancerCenter; and @DrKrinaPatel of @MDAndersonNews. 📺https://t.co/qx9tmmYiu5 https://t.co/B0kiTiJHFK
-
-
Mashup Score: 12Get to Know ... Catherine Coombs, MD - 7 month(s) ago
Dr. Coombs, an Associate Professor in the Division of Hematology/Oncology at the University of California, Irvine (UCI) School of Medicine, discusses her journey into oncology, what it’s like to broach both the lymphoid and myeloid worlds, and a unique skill she’s lucky to have. Where did you grow up, and when did you know you wanted to be a physician? I grew up in the Cincinnati, Ohio, area. I decided to be a physician a bit later than most. I went to college as an economics major but switched to a
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
In the latest Get to Know feature, @calliecoombsmd of @UCIrvine discusses her journey into oncology, what it’s like to broach both the lymphoid and myeloid worlds, and a unique skill she’s lucky to have. 📚https://t.co/mJQkVaqJ5p https://t.co/D49h3kZjXy
-
Nine cases of secondary malignancies were reported among 169 patients who received rusfertide treatment, according to a study presented by @doctorpemm of @MDAndersonNews at #MPNCongress2023. Learn more: https://t.co/khGOGwRH26 https://t.co/xSGE6w50AE